The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Biogen (I); Fujifilm; Genzyme (I); Ipsen; Novartis (I); Teva (I)
Speakers' Bureau - Biogen (I); Genzyme (I); Ipsen; Novartis (I); Taiho Pharmaceutical; Teva (I)
Research Funding - Ambry Genetics (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Idera (Inst); Lilly (Inst); MabVax (Inst); Minneamrita Therapeutics (Inst); Pharmacyclics (Inst); Samumed (Inst)
First-in-human study of DS-6051b in patients (pts) with advanced solid tumors (AST) conducted in the US.
 
Kyriakos P. Papadopoulos
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); ArQule (Inst); Calithera Biosciences (Inst); Curegenix (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Formation Biologics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Peloton Therapeutics (Inst); Regeneron (Inst); Sanofi (Inst)
 
Leena Gandhi
Consulting or Advisory Role - AstraZeneca; Hengrui Pharmaceutical ; Ignyta; Merck Sharp & Dohme; Roche/Genentech; Syndax
Research Funding - Bristol-Myers Squibb
 
Pasi A. Janne
Stock and Other Ownership Interests - Gatekeeper Pharmaceuticals
Consulting or Advisory Role - Araxes Pharma; ARIAD; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Ignyta; Lilly; LOXO; Merrimack; Mirati Therapeutics; Pfizer; Roche/Genentech
Research Funding - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Lilly; Puma Biotechnology
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp. I receive post-marketing royalties from this invention
 
Sai-Hong Ignatius Ou
Stock and Other Ownership Interests - TP Therapeutics
Honoraria - ARIAD/Takeda; AstraZeneca; Foundation Medicine; Genentech/Roche; Novartis; Pfizer; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Foundation Medicine; Ignyta; Novartis; Pfizer; Roche/Genentech; Takeda; TP Therapeutics
Speakers' Bureau - AstraZeneca; Genentech; Takeda
Research Funding - ARIAD (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); Roche Pharma AG (Inst)
 
Alice Shaw
Honoraria - Genentech/Roche; Ignyta; Novartis; Pfizer
Consulting or Advisory Role - ARIAD; Genentech/Roche; Ignyta; Novartis; Pfizer; Takeda
Research Funding - Genentech; Novartis; Pfizer
 
Terri Robin Goldberg
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Jonathan Greenberg
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
Research Funding - Daiichi Sankyo
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Xuemin Gu
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Masaya Tachibana
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Giorgio Senaldi
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Amgen; Gilead Sciences; Pfizer
Patents, Royalties, Other Intellectual Property - Amgen
 
Ryota Shiga
Employment - Daiichi Sankyo
 
Hamim Zahir
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
Research Funding - Daiichi Sankyo
 
Kenji Nakamaru
Employment - Daiichi Sankyo
 
Erkut Borazanci
No Relationships to Disclose